Dr. Kass Discusses HER2-Positive Breast Cancer Advancements
Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
Kass says the adjuvant setting has produced positive results, which has allowed he and his colleagues to effectively palliate metastatic patients better than ever before. However, optimal sequencing is still being determined.
Some metastatic malignancies can now be managed as chronic illnesses, says Kass. By being able to control these malignancies, Kass and his colleagues are now seeing recurrences of metastases to the central nervous system (CNS) as the limiting factor for quality and quantity of life.
Fred C. Kass, MD, oncology/hematology, internal medicine, Cancer Center of Santa Barbara, discusses HER2-positive breast cancer advancements.
Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC
April 22nd 2024During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.
Read More
